pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. This is the industry’s definitive antigen specific drug development forum.

Immunity 52

Immunity Immunization Medical Schools Drug Development 52

pharmaphorum

APRIL 20, 2021

The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. The post Non-Small Cell Lung Cancer Drug Development Summit appeared first on. View the event guide now for more details!

Drug Development 52

Drug Development Medical Schools Immunity Immunization 52

STAT

MARCH 6, 2023

“I’m slowly running out of options,” said Young, 62, who in November began   receiving   a five-month series of shots at a clinic near her San Francisco home; the vaccine is designed to teach her immune cells to recognize and combat tumors.

Vaccines 246

Vaccines Bioethics Immunity Immunization 246

pharmaphorum

NOVEMBER 11, 2022

Pick the brains of 140+ senior level drug developers across industry and academia at the physical return of the only meeting dedicated to overcoming challenges in biomarker understanding, disease selection and clinical translation in inflammasome-centered drug development.

Medical Schools 52

Medical Schools Immunity Immunization Hospitals 52

European Pharmaceutical Review

AUGUST 9, 2024

Potential of nipocalimab for HDFN “Nipocalimab is the only drug in development with the potential to treat a variety of alloimmune diseases that affect the foetus such as foetal/neonatal alloimmune thrombocytopenia and immune-mediated congenital heart block,” lead study investigator Dr Kenneth Moise Jr. ,

Medical Schools 52

Medical Schools Immunity Immunization Drug Development 52

European Pharmaceutical Review

DECEMBER 28, 2023

As well as presenting recent findings from the pivotal AFM13-104 study, Andreas also reflects on the challenges encountered and conquered in developing Affimed’s innate cell engager, Acimtamig, which targets CD30 on lymphoma cells and CD16A on NK cells. at the Hannover Medical School, Germany, and spent his career as a practicing oncologist.

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

Pharmaceutical Technology

APRIL 24, 2023

In an email to this news service, João Conde, PhD, professor at NOVA Medical School, Universidade NOVA de Lisboa, said advances like the mRNA vaccines serve as a testament to the breakthroughs made by science over decades of research at the junction of genetics and nanomedicine.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59